Updates in Pharmacotherapy for Weight Loss and Infectious Disease

Course overview

At the conclusion of this program, the participant will be able to:   Session 2A-Obesity and Weight Loss : 1) Review risk factors and criteria within obesity 2) Describe appropriate patient populations for weight loss pharmacotherapy. 3) Delineate key characteristics of various pharmacotherapy options including GLP-1 agonists. 4) Apply knowledge within patient cases to select an appropriate pharmacotherapy option.   Session 2B-New Antimicrobials, Penicillin Allergy De-labeling, Shorter Durations of Therapy, and IV to PO conversion and new HIV PreP: 5. Review various new FDA-approved antimicrobials.   6. Evaluate these agents critically for use in clinical practice. 7. Review new drugs for prevention of HIV infection (HIV PreP) in high risk individuals. 8. Discuss penicillin allergies including long-term implications. 9. Describe process and recent data supporting intervention strategies to de-label patients. 10. Describe disease states for which shorter durations of therapy data are growing. 11. Review data for which IV to PO conversion is growing for complicated infections.